Archival Report| Volume 65, ISSUE 7, P607-613, April 01, 2009

Download started.


An Exploration of the Effect of Modafinil on Olanzapine Associated Weight Gain in Normal Human Subjects

  • James L. Roerig
    Address reprint requests to James L. Roerig, Pharm.D., B.C.P.P., University of North Dakota School of Medicine and Health Sciences, Clinical Neuroscience, PO Box 1415, 120 South 8th Street, Suite 201, Fargo, ND 58107-1415
    University of North Dakota School of Medicine and Health Sciences, Fargo, North Dakota

    The Neuropsychiatric Research Institute, Fargo, North Dakota
    Search for articles by this author
  • Kristine J. Steffen
    University of North Dakota School of Medicine and Health Sciences, Fargo, North Dakota

    The Neuropsychiatric Research Institute, Fargo, North Dakota
    Search for articles by this author
  • James E. Mitchell
    University of North Dakota School of Medicine and Health Sciences, Fargo, North Dakota

    The Neuropsychiatric Research Institute, Fargo, North Dakota
    Search for articles by this author
  • Ross D. Crosby
    University of North Dakota School of Medicine and Health Sciences, Fargo, North Dakota

    The Neuropsychiatric Research Institute, Fargo, North Dakota
    Search for articles by this author
  • Blake A. Gosnell
    Department of Food Science & Nutrition, University of Minnesota, St. Paul, Minnesota
    Search for articles by this author
Published:December 22, 2008DOI:


      Weight gain has been associated with many second generation antipsychotics (SGAs). A variety of theories have been put forward as to the etiology of SGA-associated weight gain. Modafinil possesses pharmacologic effects that could influence the weight gain associated with SGAs. The objective of this trial was to determine the effect of modafinil on olanzapine-associated weight gain.


      This study was a 3-week, randomized, double-blind, placebo-controlled trial. All subjects received olanzapine titrated to 10 mg/day. Concurrently, subjects were randomized to receive modafinil titrated to 200 mg/day or placebo. Weight and feeding lab assessments were conducted at baseline and endpoint.


      Fifty subjects were enrolled in the study with 20 subjects per group completing the trial. The primary outcome variable was change in the body mass index (BMI) over the 3 weeks of the trial. Increases in BMI were observed in both groups. However, analysis of covariance, controlled for baseline BMI, revealed that the olanzapine/placebo group had a greater increase in BMI at end point compared with the olanzapine/modafinil group (.89 ± .59 vs. .47 ± .50 kg/m2, p < .05). When controlled for gender, the comparison showed a significant difference between groups at week 1 but not at weeks 2 or 3.


      The results of this trial should not be extrapolated to clinical practice at this time. These data do serve to support further evaluation in a patient population to determine if the weight modifying effect of modafinil can be demonstrated over a longer period of time.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lieberman J.A.
        • Stroup T.S.
        • McEvoy J.P.
        • Swartz M.S.
        • Rosenheck R.A.
        • Perkins D.O.
        • et al.
        • Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators
        Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
        N Engl J Med. 2005; 353: 1209-1223
        • Casey D.E.
        Implications of the CATIE trial on treatment: Extrapyramidal symptoms.
        CNS Spectr. 2006; 11: 25-31
        • Green A.I.
        • Lieberman J.A.
        • Hamer R.M.
        • Glick I.D.
        • Gur R.E.
        • Kahn R.S.
        • et al.
        Olanzapine and haloperidol in first episode psychosis: Two-year data.
        Schizophr Res. 2006; 86: 234-243
        • Allison D.B.
        • Mentore J.L.
        • Heo M.
        • Chandler L.P.
        • Cappelleri J.C.
        • Infante M.C.
        • et al.
        Antipsychotic-induced weight gain: a comprehensive research synthesis.
        Am J Psychiatry. 1999; 156: 1686-1696
        • Wirshing D.A.
        • Spellberg B.J.
        • Erhart S.M.
        • Marder S.R.
        • Wirshing W.C.
        Novel antipsychotics and new onset diabetes.
        Biol Psychiatry. 1998; 4: 778-783
        • Gentile S.
        Long-term treatment with atypical antipsychotics and the risk of weight gain: A literature analysis.
        Drug Saf. 2006; 29: 303-319
        • Fakhouri W.
        Extent of distress caused by adverse experiences associated with antipsychotic treatment.
        Eur Neuropsychopharmacol. 1999; 9: S285
        • Sachs G.S.
        • Guille C.
        Weight gain associated with use of psychotropic medications.
        J Clin Psychiatry. 1999; 60: 16-19
        • Kawachi I.
        Physical and psychological consequences of weight gain.
        J Clin Psychiatry. 1999; 60: 5-9
        • Roerig J.L.
        • Mitchell J.E.
        • de Zwaan M.
        • Crosby R.D.
        • Gosnell B.A.
        • Steffen K.J.
        • et al.
        A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors.
        J Clin Psychopharmacol. 2005; 25: 413-418
        • Peuskens J.
        • Link C.G.
        A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia.
        Acta Psychiatr Scand. 1997; 96: 265-273
        • McIntyre R.S.
        • Mancini D.A.
        • Basile V.S.
        Mechanisms of antipsychotic-induced weight gain.
        J Clin Psychiatry. 2001; 62: 23-29
        • Theisen F.M.
        • Haberhausen M.
        • Firnges M.A.
        • Fleischhaker C.
        • Clement H.W.
        • Heinzel-Gutenbrunner M.
        • et al.
        No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation.
        Pharmacogenomics J. 2007; 7: 275-281
        • Kroeze W.K.
        • Hufeisen S.J.
        • Popadak B.A.
        • Renock S.M.
        • Steinberg S.
        • Ernsberger P.
        • et al.
        H 1 - histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
        Neuropsychopharmacology. 2003; 28: 519-526
        • Matsui-Sakata A.
        • Ohtani H.
        • Sawada Y.
        Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus.
        Drug Metab Pharmacokinet. 2005; 20: 368-378
        • Kim S.F.
        • Huang A.S.
        • Snowman A.M.
        • Teuscher C.
        • Snyder S.H.
        Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
        Proc Natl Acad Sci U S A. 2007; 104: 3456-3459
        • Minzenberg M.J.
        • Carter C.S.
        Modafinil: A review of neurochemical actions and effects on cognition.
        Neuropsychopharmacology. 2007; 33: 1477-1502
        • Ishizuka T.
        • Sakamoto Y.
        • Sakurai T.
        • Yamatodani A.
        Modafinil increases histamine release in the anterior hypothalamus of rats.
        Neurosci Lett. 2003; 339: 143-146
        • Bastuji H.
        • Jouvet M.
        Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil.
        Prog Neuropsychopharmacol Biol Psychiatry. 1988; 12: 695-700
        • Touret M.
        • Sallanon-Moulin M.
        • Jouvet M.
        Awakening properties of modafinil without paradoxical sleep rebound: A comparative study with amphetamine in the rat.
        Neurosci Lett. 1995; 189: 43-46
        • Deroche-Gamonet V.
        • Darnaudery M.
        • Bruins-Slot L.
        • Piat F.
        • Le Moal M.
        • Piazza P.V.
        Study of the addictive potential of modafinil in naive and cocaine experienced rats.
        Psychopharmacology (Berl). 2002; 161: 387-395
        • Baptista T.
        • ElFakih Y.
        • Uzcátegui E.
        • Sandia I.
        • Tálamo E.
        • Araujo de Baptista E.
        • Beaulieu S.
        Pharmacological management of atypical antipsychotic-induced weight gain.
        CNS Drugs. 2008; 22: 477-495
        • First M.B.
        • Spitzer R.
        • Gibbon M.
        • Williams J.B.W.
        Structured Clinical Interview for DSM-IV Axis I Disorders.
        (Patient Edition, SCID-I/P, Version 2.0) New York State Psychiatric Institute, New York1995
        • Fairburn C.G.
        • Cooper Z.
        The eating disorder examination.
        in: Fairburn C.G. Wilson G.T. Binge Eating: Nature, Assessment and Treatment. 12th ed. Guilford Press, New York1993: 317-360
        • Simpson G.M.
        • Angus J.W.
        A rating scale for extrapyramidal side effects.
        Acta Psychiatr Scand Suppl. 1970; 212: 11-19
        • Barnes T.R.
        A rating scale for drug induced akathisia.
        Br J Psychiatry. 1989; 154: 672-676
        • Guy W.
        Abnormal involuntary movements.
        in: Guy W. ECDUE Assessment Manual for Psychopharmacology. National Institute of Mental Health, Rockville, MD1976
        • White M.A.
        • Whisenhunt B.L.
        • Williamson D.A.
        • Greenway F.L.
        • Netemeyer R.G.
        Development and validation of the food-craving inventory.
        Obes Res. 2002; 10: 107-114
        • Johns M.W.
        A new method for measuring daytime sleepiness: The Epworth sleepiness scale.
        Sleep. 1991; 14: 540-545
        • Jarvis B.G.
        MediaLab Research Software.
        ([computer program]) Empirisoft, New York2006
        • University of Minnesota, Nutrition Coordinating Center
        Nutrition Data System for Research (NDS-R).
        University of Minnesota, Division of Epidemiology and Community Health, School of Public Health, Minneapolis1998
        • Cohen J.
        Statistical Power Analysis for the Behavioral Sciences.
        2nd ed. Lawrence Erlbaum, Hillsdale, NJ1988
        • Cohen J.
        Eta-squared and partial eta-squared in fixed factor ANOVA designs.
        Educ Psychol Meas. 1973; 33: 107-112
        • Henderson D.C.
        • Louie P.M.
        • Koul P.
        • Namey L.
        • Daley T.B.
        • Nguyen D.D.
        Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient.
        Ann Clin Psychiatry. 2005; 17: 95-97
        • Makris A.P.
        • Rush C.R.
        • Frederich R.C.
        • Kelly T.H.
        Wake-promoting agents with different mechanisms of action: Comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity.
        Appetite. 2004; 42: 185-195
        • Navarro V.J.
        • Senior J.R.
        Drug-related hepatotoxicity.
        N Engl J Med. 2006; 354: 731-739
        • Hunter M.D.
        • Ganesan V.
        • Wilkinson I.D.
        • Spence S.A.
        Impact of modafinil on prefrontal executive function in schizophrenia.
        Am J Psychiatry. 2006; 163: 2184-2186
        • Turner D.C.
        • Clark L.
        • Pomarol-Clotet E.
        • McKenna P.
        • Robbins T.W.
        • Sahakian B.J.
        Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia.
        Neuropsychopharmacology. 2004; 29: 1363-1373
        • Rosenthal M.H.
        • Bryant S.L.
        Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia.
        Clin Neuropharmacol. 2004; 27: 38-43
        • Sevy S.
        • Rosenthal M.H.
        • Alvir J.
        • Meyer S.
        • Visweswaraiah H.
        • Gunduz-Bruce H.
        • Schooler N.R.
        Double-blind, placebo controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications.
        J Clin Psychiatry. 2005; 66: 839-843
        • Vorspan F.
        • Warot D.
        • Consoli A.
        • Cohen D.
        • Mazet P.
        Mania in a boy treated with modafinil for narcolepsy.
        Am J Psychiatry. 2005; 162: 813-814
        • Wolf J.
        • Fiedler U.
        • Anghelescu I.
        • Schwertfeger N.
        Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil.
        J Clin Psychiatry. 2006; 67: 1817
        • Frye M.A.
        • Grunze H.
        • Suppes T.
        • McElroy S.L.
        • Keck Jr, P.E.
        • Walden J.
        • et al.
        A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression.
        Am J Psychiatry. 2007; 164: 1242-1249
        • Wong Y.N.
        • Simcoe D.
        • Hartman L.N.
        • Laughton W.B.
        • King S.P.
        • McCormick G.C.
        • et al.
        A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers.
        J Clin Pharmacol. 1999; 39: 30-40
        • Randall D.C.
        • Shneerson J.M.
        • Plaha K.K.
        • File S.E.
        Modafinil affects mood, but not cognitive function, in healthy young volunteers.
        Hum Psychopharmacol. 2003; 18: 163-173
        • Baptista T.
        • Kin N.M.
        • Beaulieu S.
        • de Baptista E.A.
        Obesity and related metabolic abnormalities during antipsychotic drug administration: Mechanisms, management and research perspectives.
        Pharmacopsychiatry. 2002; 35: 205-219
        • Gentile S.
        Long-term treatment with atypical antipsychotics and the risk of weight gain: A literature analysis.
        Drug Saf. 2006; 29: 303-319
        • Seeman M.V.
        Gender differences in the prescribing of antipsychotic drugs.
        Am J Psychiatry. 2004; 161: 1324-1333
        • Basson B.R.
        • Kinon B.J.
        • Taylor C.C.
        • Szymanski K.A.
        • Gilmore J.A.
        • Tollefson G.D.
        Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
        J Clin Psychiatry. 2001; 62: 231-238
        • Ascher-Svanum H.
        • Stensland M.
        • Zhao Z.
        • Kinon B.J.
        Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
        BMC Psychiatry. 2005; 5: 3